TABLE 1.
Effects of adenosinergic drugs on psychostimulant-induced hyperlocomotion: The full (IUPAC) names of the drugs are: APEC (2-[(2-aminoethylamino)carbonylethylphenylethylamino[-5'-N-ethylcarboxamidoadenosine), caffeine (1,3,7-trimethylxanthine), CGS21680 (2-(4-(2-carboxyethyl)phenylethylamino)adenosine-5'-N-ethylcarboxamideadenosine), CHA (N6-cyclohexyladenosine), CLA (2-chloroadenosine), CPA (N6-cyclopentyladenosine), CPT (8-cyclopentyltheophylline), CPX (8-cyclopentyl-1,3-dipropylxanthine), CV-1808 (2-(phenylamino)adenosine), DPMA (N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine), DMPX (3,7-dimethyl-1-propargylxanthine), L-PIA (L-N6-phenylisopropyladenosine), NECA (5'-(N-ethylcarboxamido)-adenosine), R-PIA (R-N6-phenylisopropyladenosine), theophylline (1,3-dimethyl-7H-purine-2,6-dione). ↓ / ↑: attenuates / potentiates the drug-induced effect on locomotor activity; ↔ no effect
| • Drug used to induced hyperlocomotion | ||||
|---|---|---|---|---|
| Dopamine receptor agonists | Adenosinergic action | Drug | Effect | References |
| Amphetamine | A1R agonist | 2-CLA | ↓ | Heffner et al., 1989 |
| CHA | ↓ | Heffner et al., 1989 | ||
| Turgeon et al., 1996 | ||||
| CPA | ↓ | Heffner et al., 1989 | ||
| Poleszak and Malec, 2002 | ||||
| PIA | ↓ | Heffner et al., 1989 | ||
| A2AR agonist | APEC | #x2193; | Turgeon et al., 1996 | |
| CGS 21680 | #x2193; | Popoli et al., 1994 | ||
| Rimondin et al., 1997 | ||||
| Poleszak and Malec, 2002 | ||||
| Sills et al., 2001 | ||||
| A2R agonist | CV-1808 | #x2193; | Heffner et al., 1989 | |
| A1R/A2R agonist | NECA | #x2193; | Heffner et al., 1989 | |
| Shi et al., 1994 | ||||
| Poleszak and Malec, 2002 | ||||
| A2AR antagonist | DMPX | ↑ | Poleszak and Malec, 2002 | |
| A1R/A2R antagonist | Caffeine | ↑ | ||
| Cocaine | A1R agonist | CPA | #x2193; | Poleszak and Malec, 2002 |
| A2AR agonist | CGS 21680 | #x2193; | ||
| A1R/A2R agonist | NECA | #x2193; | Shi et al., 1994 | |
| Poleszak and Malec, 2002 | ||||
| A1R antagonist | CPT | ↔ | Poleszak and Malec, 2002 | |
| A2AR antagonist | DMPX | ↑ | ||
| A1R/A2R antagonist | Caffeine | ↑ | ||
| SKF38393 (D1R agonist) | A1R agonist | CPA | #x2193; | Ferré et al., 1994 |
| A1R antagonist | 8-CPT2 | ↑ | Popoli et al., 1996 | |
| Bromocriptine (D2R agonist) | A1R agonist | CPA | ↔ | Ferré et al., 1994 |
| L-PIA | #x2193; | Ferré et al., 1991b | ||
| A1R/A2R agonist | NECA | #x2193; | Ferré et al., 1991b | |
| A1R/A2R antagonist | Caffeine | ↑ | Ferré et al., 1991a | |
| Theophylline | ↑ | |||
| NMDAR channel blockers | Adenosinergic action | Drug | Effect | References |
|---|---|---|---|---|
| MK-801 | A1R agonist | CPA | #x2193; | Malec and Poleszak, 2006 |
| ↔ | Fraser et al., 1997 | |||
| A2AR agonist | CGS 21680 | #x2193; | Malec and Poleszak, 2006 | |
| DPMA | #x2193; | Fraser et al., 1997 | ||
| A1/A2R agonist | NECA | #x2193; | Malec and Poleszak, 2006 | |
| A1R antagonist | CPT | ↔ | ||
| A2AR antagonist | DPMX | ↑ | Malec and Poleszak, 2006 | |
| A1R/A2AR antagonist | Caffeine | ↑ | Kuribara et al., 1992 | |
| #x2193; | de Oliveira et al., 2005 | |||
| #x2193; | Dall'lgna et al., 2003 | |||
| Theophylline | ↑ | Malec and Poleszak, 2006 | ||
| PCP | A1R agonist | CPA | #x2193; | Gotoh et al., 2002 |
| A2AR agonist | CGS 21680 | #x2193; | Rimondini etal., 1997 | |
| Ketamine | A1R antagonist | DPCPX | ↔ | Mandryk et al., 2005 |
| A2AR antagonist | DMPX | ↑ | ||
| A1R/A2R antagonist | Caffeine | ↑ |